Full Text
A cost utility analysis of CYP2D6 pharmacogenetic guided dosing versus standard dosing of risperidone for treatment of schizophrenia

Abstract

Authors

T. Yep B. Devine

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×